Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.

An estimated 5 % of breast cancers and 10 % of ovarian cancers may be due to inherited autosomal dominant breast and ovarian cancer alleles BRCA1 und BRCA2. According to population-based studies 1 or 2 women per 1000 carry such a risk allele. The cumulative cancer risk for healthy women with a BRCA-mutation is between 60 and 85 % for breast cancer and between 20 and 60 % for ovarian cancer. Recent studies have reported an increased risk for contralateral breast cancer in women after unilateral breast cancer. Since 1997 the German Cancer Aid has supported an interdisciplinary approach for high-risk women consisting of genetic testing, counselling and prevention in 12 specialised centres. Since 2005 this concept has received additional support from health insurance companies, and results have been assessed with regard to outcomes (e.g. reduced mortality due to more intensive early diagnosis). The number of centres has increased to 15 at various university hospitals. These interdisciplinary centres offer women the opportunity to participate in a structured screening programme for the early diagnosis of breast cancer and provide non-directive counselling on the options for risk-reducing surgery, e.g., prophylactic bilateral salpingo-oophorectomy, prophylactic bilateral mastectomy or contralateral prophylactic mastectomy after unilateral breast cancer. Such surgical interventions can significantly reduce the risk of disease, the respective disease-specific mortality and - particularly prophylactic bilateral salpingo-oophorectomy - total mortality in BRCA-mutation carriers.

[1]  M. Golatta,et al.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study , 2012, Breast Cancer Research.

[2]  Nina Ditsch,et al.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. , 2011, Deutsches Arzteblatt international.

[3]  V. Kaklamani Risk-Reducing Surgery in , 2010 .

[4]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[5]  U. Bick,et al.  Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Jacobs,et al.  BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark , 2008, Clinical Cancer Research.

[7]  O. Olopade,et al.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[9]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[10]  T. Rebbeck,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2004 .

[11]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[13]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[14]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[15]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[16]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[17]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[18]  J. Dungan Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[19]  E. Friedman,et al.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.